Ruthenium metallodendrimer against triple-negative breast cancer in mice

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..

Carbosilane metallodendrimers, based on the arene Ru(II) complex (CRD13) and integrated to imino-pyridine surface groups have been investigated as an anticancer agent in a mouse model with triple-negative breast cancer. The dendrimer entered into the cells efficiently, and exhibited selective toxicity for 4T1 cells. In vivo investigations proved that a local injection of CRD13 caused a reduction of tumour mass and was non-toxic. ICP analyses indicated that Ru(II) accumulated in all tested tissues with a greater content detected in the tumour.

Media Type:

Electronic Article

Year of Publication:

2023

Publication:

2023

Contained In:

To Main Record - volume:53

Contained In:

Nanomedicine : nanotechnology, biology, and medicine - 53(2023) vom: 15. Aug., Seite 102703

Language:

English

Contributors:

Michlewska, Sylwia [Author]
Wójkowska, Dagmara [Author]
Watala, Cezary [Author]
Skiba, Elżbieta [Author]
Ortega, Paula [Author]
de la Mata, Francisco Javier [Author]
Bryszewska, Maria [Author]
Ionov, Maksim [Author]

Links:

Volltext

Keywords:

Anticancer agent
In vivo
Journal Article
Ruthenium metallodendrimer
Toxicity
Tumour weight

Notes:

Date Revised 27.08.2023

published: Print-Electronic

Citation Status Publisher

doi:

10.1016/j.nano.2023.102703

funding:

Supporting institution / Project title:

PPN (Catalogue-ID):

NLM360979262